Takeda ( TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results